Dengue Vaccine Market Analysis, Size, and Share by 2031

The Dengue Vaccine Market is expected to register a CAGR of 11.3% from 2025 to 2031, with a market size expanding from US$ XX million in 2024 to US$ XX Million by 2031.

The report is segmented by Product (CYD-TDV), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies, Others). The global analysis is broken down at the regional level and for major countries. The market evaluation is presented in US$ for the above segmental analysis.

Purpose of the Report

The report Dengue Vaccine Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:

• Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
• Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
• Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.

Dengue Vaccine Market Segmentation

Product

• CYD-TDV

Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores
• Online Pharmacies

• Get Top Key Market Trends of this report.
  This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Free Sample PDF

Dengue Vaccine Market Growth Drivers

• Rising Incidence of Dengue Fever: The increasing incidence of dengue fever globally is a key growth driver for the dengue vaccine market. As urbanization and climate change cause an expansion of mosquito populations, dengue fever is becoming more widespread, particularly in tropical and subtropical areas. The World Health Organization (WHO) reports that dengue affects 100-400 million people annually, with significant outbreaks in regions like Southeast Asia, South America, and parts of Africa. This increase in cases has highlighted the urgent need for effective vaccines to prevent the spread of the disease. Rising incidences of severe forms, such as dengue hemorrhagic fever and dengue shock syndrome, are pushing healthcare systems to focus on vaccination as a primary preventative measure. Forecasts predict that as the number of infections continues to rise, demand for vaccines will expand, resulting in a larger market size. Additionally, governments are prioritizing dengue control programs, which increases funding for vaccines and drives their accessibility. The global burden of dengue fever is projected to grow, which means that vaccine development and distribution are expected to see substantial investments, contributing to the expansion of the market. The growing burden on healthcare infrastructure due to dengue will propel the growth of the vaccine market and significantly increase its market share.
• Technological Advancements in Vaccine Development: Technological advancements in vaccine development have been crucial in the growth of the dengue vaccine market. With growing investments in biotechnology and research, new technologies are enabling the creation of more effective, safe, and accessible vaccines. The dengue vaccine market has seen considerable advancements, particularly in the development of vaccines that provide broader protection across the four different serotypes of the dengue virus. For example, Sanofi Pasteur's Dengvaxia, the first licensed dengue vaccine, marked a significant step forward. Furthermore, ongoing research and development are exploring novel vaccine platforms such as mRNA technology and recombinant DNA technologies, which promise higher efficiency and safety. Market forecasts indicate that these innovations will continue to propel the market, allowing for the development of vaccines with improved efficacy and fewer side effects. The trend toward multivalent vaccines that offer protection against all four dengue virus serotypes is also growing, which will help expand the market further. Additionally, advancements in vaccine production techniques, including more cost-effective and scalable manufacturing processes, are expected to lower production costs, making vaccines more accessible to populations in low-income regions. This will increase market penetration in endemic areas where the burden of dengue fever is the highest. Therefore, technological progress in vaccine development continues to be a major driver of market growth.
• Increased Public Awareness and Education on Dengue Fever: Public awareness and education on the dangers of dengue fever are key drivers for the growth of the dengue vaccine market. As dengue outbreaks become more frequent and impactful, public health campaigns aimed at educating individuals about preventive measures, symptoms, and the importance of vaccination are becoming more common. Governments and non-governmental organizations (NGOs) have invested heavily in raising awareness through media, community outreach programs, and educational initiatives. Market forecasts indicate that as more people become aware of the risks associated with dengue and the availability of preventive measures such as vaccines, the demand for vaccines will increase. This trend is expected to drive vaccine adoption rates, particularly in regions where dengue is endemic. The enhanced understanding of dengue fever’s long-term effects and the importance of vaccination in preventing severe illness, such as hemorrhagic fever, is fueling the growth of the dengue vaccine market and encouraging more people to seek vaccination.

Dengue Vaccine Market Future Trends

• Development of Multivalent Dengue Vaccines: A key trend that is shaping the dengue vaccine market is the development of multivalent vaccines. Traditional vaccines have typically targeted a single serotype of the dengue virus, but researchers are now focusing on multivalent vaccines that can protect against all four serotypes. This is important because infection with one serotype does not provide immunity to the others, and people can be infected multiple times by different serotypes. Multivalent vaccines offer a more comprehensive solution by providing broad protection against all strains of the dengue virus. Market forecasts predict that these vaccines will dominate the market in the future, as they hold the potential to significantly reduce the incidence of dengue fever. Vaccine manufacturers are focusing on improving the safety and efficacy of multivalent vaccines to ensure their effectiveness across diverse populations. By providing immunity to all four serotypes, multivalent vaccines will reduce the risk of severe dengue and contribute to the global effort to eradicate the disease. The increasing development of these vaccines represents an exciting trend, as they address a key challenge in dengue prevention. With a broader range of protection, these vaccines will likely see greater adoption in endemic regions, driving both market size and market share.
• Integration of Dengue Vaccines in National Immunization Programs: An emerging trend in the dengue vaccine market is the integration of vaccines into national immunization programs in countries with high levels of dengue transmission. Governments and health organizations are increasingly recognizing the importance of including dengue vaccines as part of routine vaccination schedules, alongside vaccines for other infectious diseases. Market forecasts suggest that this trend will continue to grow, as the inclusion of dengue vaccines in national programs ensures widespread vaccination coverage and helps to protect vulnerable populations. National immunization programs are crucial for providing equitable access to vaccines, particularly in low- and middle-income countries where the disease burden is highest. By integrating dengue vaccines into public health initiatives, governments are improving vaccine accessibility, reducing the financial barriers that might prevent people from receiving the vaccine. This will drive increased demand for vaccines, as more people are reached through these programs. Additionally, global health organizations such as the World Health Organization (WHO) support the integration of dengue vaccines into national programs, providing technical guidance and financial assistance. This trend will contribute to an increased market share for dengue vaccine manufacturers, as more countries adopt these vaccines as part of their public health strategies.
• Focus on Vaccine Safety and Efficacy Monitoring: A growing trend in the dengue vaccine market is the increasing focus on the safety and efficacy monitoring of vaccines. As dengue vaccines become more widely distributed, ensuring their long-term safety and effectiveness is crucial to maintaining public confidence. Vaccine manufacturers and regulatory agencies are placing significant emphasis on post-marketing surveillance to monitor any potential adverse effects and evaluate the long-term immunity provided by the vaccine. Market forecasts indicate that as more data becomes available from real-world use, the safety profiles of dengue vaccines will be further established, leading to greater acceptance among the population. This trend is particularly important in regions where vaccine hesitancy may exist due to concerns about safety. Ensuring the ongoing safety of vaccines and addressing any side effects that may arise will help to maintain high vaccination rates and support broader vaccine adoption. Furthermore, monitoring the efficacy of vaccines in different populations will provide valuable insights for the development of next-generation vaccines. This focus on safety and efficacy will strengthen the overall market, increase public trust, and drive the adoption of dengue vaccines globally.

Dengue Vaccine Market Opportunities

• Increased Investment in Vaccine Research and Development: The dengue vaccine market presents significant opportunities in research and development (R&D), as investment in innovative vaccine technologies continues to rise. Pharmaceutical companies and research organizations are prioritizing R&D efforts to create more effective and affordable vaccines. This investment is expected to drive the development of next-generation vaccines that provide greater protection against the four serotypes of the dengue virus. Market forecasts predict that as R&D activities increase, the global market for dengue vaccines will expand, offering new revenue streams for manufacturers. Additionally, breakthroughs in vaccine production technologies, such as mRNA-based vaccines, will help reduce costs and improve production efficiency. As governments, NGOs, and private organizations continue to collaborate on vaccine development, access to vaccines will improve, especially in low-income countries where the disease burden is highest. The increased focus on R&D also holds the potential for new therapeutic vaccines, which could help address the growing number of dengue cases and reduce the public health burden.
• Introduction of Low-Cost Dengue Vaccines: The development of low-cost dengue vaccines presents a significant opportunity for the market, particularly in low- and middle-income countries. Dengue vaccination is crucial for the control of the disease, but high vaccine costs have been a barrier to widespread adoption in developing regions, where the disease burden is the highest. By creating cost-effective vaccine solutions, manufacturers can increase access to vaccines, ensuring that they reach populations most at risk. Market forecasts suggest that low-cost vaccines will be a key factor in expanding market reach and improving public health outcomes. Through advances in vaccine production and partnerships between public and private sectors, the cost of dengue vaccines is expected to decrease. This will make vaccines more affordable for both governments and individuals, driving greater market penetration in regions with limited resources. Additionally, pricing strategies such as tiered pricing or subsidies from international organizations can help make vaccines more accessible in endemic countries. As low-cost vaccines become more widely available, demand is expected to increase, which will contribute to the overall growth of the dengue vaccine market. This opportunity aligns with global public health goals to eliminate dengue and prevent its spread, particularly in underdeveloped regions where access to healthcare is limited.
• Growth in Travel-Related Vaccination Demand: The increasing global mobility and rise in international travel are creating a growing opportunity for dengue vaccines. As more people travel to dengue-endemic regions for business, tourism, or work, the demand for travel-related vaccinations is increasing. Many international travelers are seeking vaccines to protect themselves from diseases such as dengue fever. Travel clinics and healthcare providers are now offering dengue vaccines as part of their recommended vaccinations for travelers visiting high-risk areas. This growing focus on preventive healthcare for travelers is creating an additional revenue stream for vaccine manufacturers and healthcare providers. Market forecasts indicate that the increasing number of international travelers will continue to drive the demand for dengue vaccines in the coming years. As travel-related dengue vaccination becomes a standard recommendation, this opportunity is expected to expand the overall market size. The travel sector’s growing focus on health and safety, combined with increasing awareness about vector-borne diseases like dengue, will further propel vaccine adoption. Additionally, as more countries include dengue vaccines as part of travel health guidelines, the market for dengue vaccines will continue to experience growth. This trend offers a unique opportunity for manufacturers to target the travel segment, boosting their market share while contributing to global health initiatives.

Dengue Vaccine Market Regional Insights

The regional trends and factors influencing the Dengue Vaccine Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Dengue Vaccine Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

Dengue Vaccine Market Report Scope

Dengue Vaccine Market Players Density: Understanding Its Impact on Business Dynamics

The Dengue Vaccine Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.

Major Companies operating in the Dengue Vaccine Market are:

1. Sanofi Pasteur Limited
2. Takeda Pharmaceutical Company Limited
3. Merck Sharp & Dohme Corp
4. GlaxoSmithKline plc
5. GeneOne Life Science
6. Medigen Vaccine Biologics

Disclaimer: The companies listed above are not ranked in any particular order.

Key Selling Points

• Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Dengue Vaccine Market, providing a holistic landscape.
• Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
• Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
• Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.

The research report on the Dengue Vaccine Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.